Original Article
Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major
N Engl J Med 1995; 332:918-922April 6, 1995
- Abstract
Background
To determine whether the orally active iron chelator deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one) is efficacious in the treatment of iron overload in patients with thalassemia major, we conducted a prospective trial of deferiprone in 21 patients unable or unwilling to use standard chelation therapy with parenteral deferoxamine.
Methods
Hepatic iron stores were determined yearly by chemical analysis of liver-biopsy specimens or magnetic-susceptibility measurements. Detailed clinical and laboratory studies were used to monitor safety and compliance.
Results
The patients received deferiprone therapy for a mean (±SE) of 3.1±0.3 years. Ten patients in whom previous chelation therapy with deferoxamine had been ineffective had initial hepatic iron concentrations of at least 80 μmol per gram of liver, wet weight — values associated with complications of iron overload. Hepatic iron concentrations decreased in all 10 patients, from 125.3±11.5 to 60.3±9.6 μmol per gram (P<0.005), with values that were less than 80 μmol per gram in 8 of the 10 patients (P<0.005). In all 11 patients in whom deferoxamine therapy had previously been effective, deferiprone maintained hepatic iron concentrations below 80 μmol of iron per gram.
Conclusions
Oral deferiprone induces sustained decreases in body iron to concentrations compatible with the avoidance of complications from iron overload. The risk of agranulocytosis associated with deferiprone may restrict its administration to patients who are unable or unwilling to use deferoxamine.
Media in This Article
Figure 2
Initial and Final Serum Ferritin Concentrations in 21 Patients with Thalassemia Major Treated with Deferiprone.Figure 1
Initial and Final Hepatic Iron Concentrations in 21 Patients with Thalassemia Major Treated with Deferiprone.Article Activity
- Article
In patients with thalassemia major, a regular program of transfusion sustains growth and development during childhood, but without concomitant chelation therapy, iron within the transfused red cells accumulates inexorably.1 Excess iron damages the liver, endocrine organs, and heart and may be fatal by adolescence.2 Two recent prospective trials have demonstrated that treatment with deferoxamine B mesylate can prevent the complications of iron overload and improve survival in thalassemia major.3,4 Both studies showed that the principal determinant of the clinical outcome was the magnitude of the body iron load. In patients able to take sufficient doses of deferoxamine to control the body iron load, the risk of cardiac disease and other complications was low, and survival after 15 years exceeded 90 percent. Conversely, when the body iron load was not controlled, the risk of complications was high, and the probability of survival to the age of 25 years was only about 30 percent.
Some patients are unable or unwilling to receive deferoxamine treatment, because of allergy, toxic effects,5 an inability to comply with prolonged parenteral infusions, or unavailability of the drug.1 A possible alternative to deferoxamine, the orally active iron-chelating agent deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one), has undergone preliminary evaluation in the United Kingdom, Canada, Europe, and India.6-16 Studies using the serum ferritin concentration as an indirect estimate of the body iron load suggest that the drug may be effective, but in some patients treated with deferiprone, reversible neutropenia or agranulocytosis has developed.14,17,18 This adverse effect emphasizes the need to assess the balance between risk and benefit by directly measuring the efficacy of deferiprone in reducing body iron. We report the results of a prospective study of deferiprone in patients unable or unwilling to use deferoxamine in whom the effect of deferiprone on the body iron burden was assessed with serial direct determinations of hepatic iron concentrations.
Methods
Patients
Patients with thalassemia major who were unwilling or unable to use deferoxamine and who had completed one or more years of treatment were enrolled in the trial. Each patient received transfusions at three- to four-week intervals to maintain the hemoglobin concentration at a level above 10 g per deciliter (approximately 10 g of transfused iron yearly in a 70-kg adult). Because of toxic effects of deferoxamine (hearing loss19 or metaphyseal dysplasia20), unmanageable local reactions, or infusions of less than 50 percent of the prescribed dose for at least one year, deferoxamine had been administered in doses insufficient to maintain a negative iron balance in some patients. Two patients with insulin-dependent diabetes had cardiac disease requiring medication. Fourteen patients had elevated serum alanine aminotransferase levels (77±14 U per liter [normal value, <40]); 13 had antibodies to hepatitis C. Five patients had previously undergone short-term studies to determine deferiprone-induced urinary and fecal iron excretion.11
The study was approved by the Hospital for Sick Children's human-subjects committee and by the Health Protection Branch, Health and Welfare Canada (File No. 9427-H1117-41C). The protocol for the magnetic-susceptibility studies was approved by the Committee on Human investigation, MetroHealth Medical Center, Cleveland. Written informed consent was obtained from each patient or a parent of the patient.
Patients were given a total daily dose of 75 mg of deferiprone per kilogram of body weight, to be taken orally every eight hours. Deferiprone was prepared according to published methods21 and encapsulated by Novopharm Pharmaceuticals, Toronto.
Efficacy
We assessed body iron burden by measuring the hepatic iron concentration, using chemical analysis of tissue obtained by liver biopsy or noninvasive magnetic measurements in vivo. The iron content of biopsy specimens was determined as previously described.12,22 Magnetic measurements of hepatic iron were performed with a superconducting quantum-interference-device susceptometer (Biomagnetic Technologies, San Diego, Calif.). The ability of this instrument to provide measurements of hepatic iron that are quantitatively equivalent to those obtained by a chemical analysis of tissue has been demonstrated elsewhere.22 The results of the chemical and magnetic measurements were used interchangeably. Their quantitative equivalence was verified throughout the course of the study by comparisons of paired chemical and magnetic determinations (n = 66, r = 0.98, P<0.001). Serum ferritin concentrations were measured every two months with a commercial kit (Ramco Laboratories, Houston).
To determine whether deferiprone could maintain body iron concentrations at levels below those associated with complications from iron overload, we used criteria established by two recent prospective trials of deferoxamine in patients with thalassemia.3,4 In the first trial, chelation therapy was defined as effective if the ratio of the total transfusional iron load to the cumulative use of deferoxamine was less than 0.6 mmol of iron per gram of deferoxamine; chelation therapy was considered ineffective if the ratio was greater than or equal to this value. As detailed previously,3 a regression analysis indicated that the corresponding concentration of hepatic iron was about 80 μmol of iron per gram of liver, wet weight (normal range, 1 to 9). In the present trial, chelation therapy was considered effective if the hepatic iron concentration was less than 80 μmol per gram, and ineffective if the concentration was 80 μmol per gram or greater.
In the second trial, chelation therapy was considered effective if the value of most serum ferritin measurements was less than 2500 μg per liter, whereas therapy was considered ineffective if the value of most measurements was 2500 μg per liter or greater.4 We used similar criteria in the present trial.
Safety
Safety was determined by monitoring the patients for abnormalities reported in animal studies.23-27 Serum alanine aminotransferase, electrolytes, urea nitrogen, creatinine, glucose, cholesterol, triglyceride, albumin, bilirubin, alkaline phosphatase, calcium, phosphate, magnesium, zinc, copper, amylase, and uric acid concentrations and prothrombin time were also monitored regularly.
Compliance
Compliance was assessed with the Medication Event Monitoring System,28 in which bottles with microprocessors in the caps are used to monitor the frequency of bottle opening. Patients were instructed to supplement a missed dose at the time of the subsequent dose (recorded as a delay but not as noncompliance) but not to supplement more than one missed dose, in order to avoid excessive peak deferiprone concentrations.
Statistical Analysis
Data are presented as means ±SE. Initial and final (most recent) data were compared with Student's t-test for paired data. The Fisher–Irwin exact test was used to determine the proportions of patients in two groups formed with the use of dichotomous variables. The relation between hepatic iron and serum ferritin concentrations was determined with Pearson's coefficient of correlation and a linear regression analysis. The coefficient of determination was used to estimate the proportion of variation in serum ferritin concentrations that could be accounted for by variation in hepatic iron stores. All tests were two-tailed; a P value of 0.025 was considered to indicate statistical significance.
Results
Twenty-one patients (with a mean age of 22±1.1 years; range, 7.5 to 31) received deferiprone for a mean of 3.1±0.3 years (range, 1 to 4.8), yielding a cumulative total of 756 patient-months (63 patient-years) of observation.
Efficacy
Body Iron Stores
Figure 1Figure 1
Initial and Final Hepatic Iron Concentrations in 21 Patients with Thalassemia Major Treated with Deferiprone. shows the initial and final hepatic iron concentrations in all 21 patients. The mean hepatic iron concentration decreased from 80.7±10.8 to 46.8±5.9 μmol per gram (P<0.005). In the 10 patients who had previously received ineffective chelation therapy with deferoxamine, the mean initial hepatic iron concentration was 125.3±11.5 μmol per gram. After a mean of 34.8±3.8 months of treatment with deferiprone, the mean concentration had decreased to 60.3±9.6 μmol per gram (P<0.005); in eight patients hepatic iron concentrations had fallen to a level below 80 μmol per gram (P<0.005). In the 11 patients who had previously received effective chelation therapy with deferoxamine, the mean initial hepatic iron concentration was 43.7±4.8 μmol per gram. After a mean of 37.4±5.4 months of deferoxamine therapy, the mean hepatic iron concentration was 32.5±4.3 μmol per gram (P not significant); the hepatic iron concentration remained below 80 μmol per gram in all 11 patients.Serum Ferritin Concentrations
Figure 2Figure 2
Initial and Final Serum Ferritin Concentrations in 21 Patients with Thalassemia Major Treated with Deferiprone. shows the initial and final serum ferritin concentrations in the 21 patients. The mean serum ferritin concentration declined from 3975±766 to 2546±381 μg per liter (P<0.005). Among 12 patients with initial serum ferritin concentrations equal to or exceeding 2500 μg per liter (mean, 5759±1077), the mean value decreased progressively to 3273±568 μg per liter (P<0.005) during a mean of 38.5±3.5 months of deferiprone therapy. In 5 of these 12 patients, the final serum ferritin concentrations were less than 2500 μg per liter (P<0.02). Among nine patients with initial values below 2500 μg per liter (mean, 1596±243), the mean serum ferritin concentration had not changed significantly after 33.5±6.2 months (1768±251 μg per liter).Comparison of Hepatic Iron and Serum Ferritin Concentrations
Figure 3Figure 3
Comparison of Hepatic Iron and Serum Ferritin Concentrations. compares the indirect estimation of body iron, based on the serum ferritin concentration, with the reference method, based on the hepatic iron concentration. The correlation between these measurements was significant (r = 0.73, P<0.005).Safety
Complete blood counts, obtained weekly in all patients, did not change significantly during treatment. Neither the reduction nor the cessation of deferiprone was required because of a change in the blood count in any patient.
Because of reports of deferiprone-induced thymic atrophy in animals,27 we monitored immune function in the study patients. The results of tests for T-cell subgroups, lymphocyte proliferation, candida, immunoglobulins, specific antibodies (to diphtheria, poliovirus, and measles), isohemagglutinin levels, and complement (C3, C4, and CH50) levels were similar to those in 20 patients treated with deferoxamine (unpublished data).
Annual rheumatologic examinations were performed because of reports of deferiprone-associated arthropathy.14,15 Joint pain developed in three patients, whose clinical course has been reported elsewhere.29 Because of one report of deferiprone-associated systemic lupus erythematosus,30 tests for antinuclear antibodies and rheumatoid factor were performed twice yearly; tests for anti-DNA and antihistone antibodies were performed initially and yearly. No significant changes in antinuclear antibodies or rheumatoid factor were noted; anti-DNA and antihistone antibodies were not detected at any time during the study.
Reductions in serum alanine aminotransferase levels were observed in most of the patients, whether or not they had evidence of previous hepatitis C infection. In one patient with a positive test for hepatitis C antibody, fluctuating elevations of alanine aminotransferase levels were probably related to deferiprone treatment, since they declined after the withdrawal of the drug.
The results of adrenal-stimulation tests, performed initially, after one and six months, and yearly thereafter, were normal. Decreases in serum zinc levels14 were not observed.
Compliance
Data on compliance, determined according to the Medication Event Monitoring System, were available for 19 patients during the last year of deferiprone treatment. The mean compliance rate (percentage of prescribed drug actually taken) was 85±3 percent (range, 41 to 98). The rate of compliance was very high (90±1 percent) among all but three patients; all three had also had a low rate of compliance with deferoxamine therapy. These three patients had high initial hepatic iron concentrations (88, 121, and 178 μmol per gram), which were substantially reduced (by 50, 85, and 36 percent) with deferiprone therapy, despite compliance rates of only 63, 71, and 41 percent, respectively.
Discussion
Deferoxamine therapy ameliorates hepatic, cardiac, and endocrine dysfunction; improves growth and sexual maturation; and prolongs survival in patients with iron overload.31-36 Two recent prospective trials of deferoxamine in patients with thalassemia have shown that the magnitude of the body iron burden is the principal determinant of the severity of iron-associated toxicity and of the clinical outcome.3,4 Thus, the ability of a new iron chelator to reduce body iron stores and maintain them at concentrations associated with a low risk of early death and complications of iron overload is a paramount consideration.
In this trial, we evaluated the efficacy of deferiprone by direct determination of hepatic iron concentrations. In 10 patients in whom deferoxamine had failed to reduce hepatic iron stores to a level below 80 μmol of iron per gram (levels associated with an increased risk of cardiac disease and early death), the body iron load was uniformly reduced with deferiprone (P<0.005). In 8 of the 10 patients, hepatic iron concentrations decreased to less than 80 μmol per gram. In the other two patients, both with high initial hepatic iron concentrations, iron storage was reduced by about 30 and 50 percent after 15 and 39 months of treatment, respectively. In all 11 patients in whom previous deferoxamine therapy had been considered effective, the hepatic iron concentration was maintained at a level below 80 μmol per gram, with no significant change during deferiprone therapy.
With the serum ferritin concentration used as an indirect means of assessing the body iron burden, the findings were similar, although the classification of patients according to the efficacy of previous therapy differed somewhat. In all 12 patients with initial serum ferritin concentrations equal to or exceeding 2500 μg per liter (the criterion for previously ineffective chelation therapy), deferiprone induced reductions in serum ferritin concentrations. During a mean period of 38.5±3.5 months, the mean serum ferritin concentration in these patients declined from 5759±1077 to 3273±568 μg per liter (P<0.005). Among the nine patients with initial serum ferritin concentrations below 2500 μg per liter, the mean concentration did not change significantly. These data demonstrate that deferiprone can both reduce and maintain body iron at concentrations associated with a low risk of iron-related complications.
In patients with a history of effective chelation therapy, deferiprone did not reduce body iron to a level below that achieved previously with deferoxamine. This observation is consistent with the finding that the daily dose of deferiprone used in our study (75 mg per kilogram of body weight) induces less iron excretion than the standard daily dose of deferoxamine (50 mg per kilogram).11,16 Nonetheless, deferiprone reduced body iron concentrations in all our patients with a history of ineffective chelation therapy with deferoxamine. Improved compliance almost certainly explains this apparent anomaly. Deferoxamine is the more efficient chelating agent, but the difficulty of compliance with parenteral administration limits the drug's effectiveness.36 In this study, a high rate of compliance improved the long-term effectiveness of chelation therapy with deferiprone, even in patients who had not been able to use deferoxamine successfully.
The differences in the direct and indirect means of evaluating deferiprone therapy are apparent from the data in Figure 3. These data show that a reliance on the serum ferritin concentration alone can lead to an inaccurate assessment of the body iron load in individual patients, in part because the serum ferritin concentration is influenced not only by body iron but also by ineffective erythropoiesis, ascorbate deficiency, liver disease, and other conditions that are common in patients with thalassemia.37
We used a hepatic iron concentration under 80 μmol per gram and a serum ferritin concentration under 2500 μg per liter as the criteria for effective chelation therapy to facilitate the comparison between deferiprone and deferoxamine. These values may not represent the optimal goals for the treatment of iron overload. They are derived from prospective trials lasting more than a decade,3,4 but 10 years is still too short a period for the evaluation of lifelong therapy. The optimal level of body iron, which remains to be determined, may be considerably lower than that reflected by these values.
The adverse effects of deferiprone included joint pain in one patient29 and a reversible elevation in the serum alanine aminotransferase level in another. Although not observed in our patients, severe neutropenia or agranulocytosis has been reported in 11 patients worldwide (Hoffbrand AV: personal communication). This toxic effect has been transient in all patients to date, but the possibility of its occurrence mandates regular monitoring of neutrophil counts during treatment with deferiprone. The incidence of agranulocytosis is being determined in a prospective multicenter trial in Canada, Italy, and the United States, under corporate sponsorship (Apotex Research, Toronto) and approved by the Canadian Health Protection Branch, the Italian Ministry of Health, and the U.S. Food and Drug Administration. The results of this study should determine the commercial availability of deferiprone. The costs associated with its administration, although likely to be less than those associated with parenteral administration of deferoxamine, have not yet been determined.
Our data provide direct evidence of the efficacy of deferiprone for the treatment of iron overload in patients with thalassemia major. Deferiprone decreases body iron concentrations and maintains them at levels below those associated with the complications of iron overload. Nevertheless, until the risk of agranulocytosis is determined, deferiprone should be considered as an investigational drug for patients unable or unwilling to use parenteral deferoxamine.
Supported in part by research grants from the Medical Research Council of Canada, the Ontario Heart and Stroke Foundation, the Cooley's Anemia Foundation, the National Institutes of Health (HL 42824 and AI 35827), the Food and Drug Administration (Orphan Products Grant FD-R-000532), and the National Thalassemia Foundation of Canada. Drs. Olivieri and Koren are Career Scientists of the Ontario Ministry of Health. Dr. Liu is a Career Scientist of the Ontario Heart and Stroke Foundation.
We are indebted to Dr. R. Miller of Novopharm Pharmaceuticals for encapsulation of deferiprone; to Dr. M. Spino of Apotex Research; to Drs. A. Collins, F.A. Olivieri, G.D. Sher, M.A. Baker, A. Zipursky, and J.W. Harris for helpful advice; to D. Fernandes, J. Klein, N. Klein, A. Muroff, P. Dakin, L. Dupuis, and S. Armstrong for technical assistance; and to Dr. A. Klein of the Health Protection Branch, Health and Welfare, Ottawa, Canada, for facilitating early studies of deferiprone.
Source Information
From the Department of Pediatrics, Hospital for Sick Children (N.F.O., D.M., M.B., G.K.); the Departments of Medicine (N.F.O., L.M.B., P.P.L.) and Pathology (R.G.C.), Toronto Hospital; and the Departments of Chemistry (R.A.M.) and Clinical Biochemistry (D.M.T.), University of Toronto — all in Toronto; and the Department of Medicine, MetroHealth Medical Center and Case Western Reserve University, Cleveland (G.M.B.).
Address reprint requests to Dr. Olivieri at the Hemoglobinopathy Program, Hospital for Sick Children, 555 University Ave., Toronto, ON M5G 1X8, Canada.
- References
References
1
Cohen AR . Management of iron overload in the pediatric patient. Hematol Oncol Clin North Am 1987;1:521-544
Medline2
Engle MA ,Erlandson M ,Smith CH . Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation 1964;30:698-705
Web of Science | Medline3
Brittenham GM ,Griffith PM ,Nienhuis AW , et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567-573
Full Text | Web of Science | Medline4
Olivieri NF ,Nathan DG ,MacMillan JH , et al. Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med 1994;331:574-578
Full Text | Web of Science | Medline5
Porter JB ,Huehns ER . The toxic effects of desferrioxamine. Baillieres Clin Haematol 1989;2:459-474
CrossRef | Medline6
Kontoghiorghes GJ ,Aldouri MA ,Sheppard LN ,Hoffbrand AV . 1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload. Lancet 1987;1:1294-1295
CrossRef | Web of Science | Medline7
Olivieri NF ,Koren G ,St Louis P ,Freedman MH ,McClelland RA ,Templeton DM . Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients. Semin Hematol 1990;27:101-104
Web of Science | Medline8
Vreugdenhil G ,Swaak AJ ,De Jeu-Jaspers C ,Van Eijk HG . Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) and transferrin and possible antianemic effects of L1 in rheumatoid arthritis. Ann Rheum Dis 1990;49:956-957
CrossRef | Web of Science | Medline9
Kontoghiorghes GJ ,Bartlett AN ,Hoffbrand AV , et al. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies. Br J Haematol 1990;76:295-300
CrossRef | Web of Science | Medline10
Tondury P ,Kontoghiorghes GJ ,Ridolfi-Luthy AR , et al. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major. Br J Haematol 1990;76:550-553
CrossRef | Web of Science | Medline11
Olivieri NF ,Koren G ,Hermann C , et al. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients. Lancet 1990;336:1275-1279
CrossRef | Web of Science | Medline12
Matsui D ,Klein J ,Hermann C , et al. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia. Clin Pharmacol Ther 1991;50:294-298
CrossRef | Web of Science | Medline13
Olivieri NF ,Koren G ,Matsui D , et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood 1992;79:2741-2748
Web of Science | Medline14
al-Refaie RN ,Wonke B ,Hoffbrand AV ,Wickens DG ,Nortey P ,Kontoghiorghes GJ . Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 1992;80:593-599
Web of Science | Medline15
Agarwal MB ,Gupte SS ,Viswanathan C , et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial. Br J Haematol 1992;82:460-466
CrossRef | Web of Science | Medline16
Collins AF ,Fassos FF ,Stobie SS , et al. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. Blood 1994;83:2329-2333
Web of Science | Medline17
Hoffbrand AV ,Bartlett AN ,Veys PP ,O'Connor NTJ ,Kontoghiorghes GJ . Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial. Lancet 1989;2:457-457
CrossRef | Web of Science | Medline18
Olivieri NF ,Sher GD ,MacKinnon JA , et al. The first prospective randomized trial of subcutaneous deferoxamine and the orally active iron chelating agent L1. Blood 1994;84:Suppl 1:363a-363a
Web of Science19
Olivieri NF ,Buncic JR ,Chew E , et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986;314:869-873
Full Text | Web of Science | Medline20
Olivieri NF ,Koren G ,Harris J , et al. Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol 1992;14:48-56
CrossRef | Medline21
Kontoghiorghes GJ ,Sheppard LN . Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones. Inorg Chim Acta 1987;136:L11-L11
CrossRef | Web of Science22
Brittenham GM ,Farrell DE ,Harris JW , et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982;307:1671-1675
Full Text | Web of Science | Medline23
Porter JB ,Morgan J ,Hoyes KP ,Burke LC ,Huehns ER ,Hider RC . Relative oral efficacy and acute toxicity of hydroxypyridin-4-one iron chelators in mice. Blood 1990;76:2389-2396
Web of Science | Medline24
Porter JB ,Hoyes KP ,Abeysinghe RD ,Brooks PN ,Huehns ER ,Hider RC . Comparison of the subacute toxicity and efficacy of 3-hydroxypyridin-4-one iron chelators in overloaded and nonoverloaded mice. Blood 1991;78:2727-2734
Web of Science | Medline25
Bergeron RJ ,Streiff RR ,Weigand J ,Luchetta G ,Creary EA ,Peter HH . A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine. Blood 1992;79:1882-1890
Web of Science | Medline26
Biesemeier JA, Laveglia J. 14-Day oral toxicity study in dogs with 1,2-dimethyl-3-hydroxypyrid-4-one (DMHP, L1). Waverly, N.Y.: Food and Drug Research Laboratories, 1991.
27
Schnebli HP, ed. Final report: preclinical evaluation of CGP 37 391 (L1). Biology report ERS 62/93. Basel, Switzerland: Ciba-Geigy, 1993:30.
28
Cramer JA ,Mattson RH ,Prevey ML ,Scheyer RD ,Ouellette VL . How often is medication taken as prescribed? A novel assessment technique. JAMA 1989;261:3273-3277[Erratum, JAMA 1989;262:1472.]
CrossRef | Web of Science | Medline29
Berkovitch M ,Laxer RM ,Inman R , et al. Arthropathy in thalassaemia patients receiving deferiprone. Lancet 1994;343:1471-1472
CrossRef | Web of Science | Medline30
Mehta J ,Singhal S ,Chablani A ,Revankar R ,Walvalkar A . L1-induced systemic lupus erythematosus. Indian J Hematol Blood Transfus 1991;9:33-3731
Barry M ,Flynn D ,Letsky E ,Risdon RA . Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress. BMJ 1974;2:16-20
CrossRef | Web of Science | Medline32
Cohen AR ,Martin M ,Schwartz E . Depletion of excessive liver iron stores with desferrioxamine. Br J Haematol 1984;58:369-373
CrossRef | Web of Science | Medline33
Wolfe LC ,Olivieri NF ,Sallan DL , et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985;312:1600-1603
Full Text | Web of Science | Medline34
Bronspiegel-Weintrob N ,Olivieri NF ,Tyler BJ ,Andrews DF ,Freedman MH ,Holland FJ . Effect of age at the start of iron chelation therapy on gonadal function in β-thalassemia major. N Engl J Med 1990;323:713-719
Full Text | Web of Science | Medline35
Zurlo MG ,De Stefano P ,Borgna-Pignatti C , et al. Survival and causes of death in thalassemia major. Lancet 1989;2:27-30
CrossRef | Web of Science | Medline36
Fosburg MT ,Nathan DG . Treatment of Cooley's anemia. Blood 1990;76:435-444
Web of Science | Medline37
Brittenham GM ,Cohen AR ,McLaren C , et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 1993;42:81-85
CrossRef | Web of Science | Medline
- Citing Articles (106)
Citing Articles
1
Katherine H. Thompson. 2011. Medicinal Inorganic Chemistry: Sequestration or Removal in Metal Ion Overload Disorders. .
CrossRef2
Saumya Shekhar Jamuar, Angeline Hwei Meeng Lai, Ah Moy Tan, Mei Yoke Chan, Ee Shien Tan, Ivy Swee Lian Ng. (2011) Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia. Journal of Paediatrics and Child Healthno-no
CrossRef3
E. A. Rachmilewitz, P. J. Giardina. (2011) How I treat thalassemia. Blood 118:13, 3479-3488
CrossRef4
Nantasit Luangasanatip, Nathorn Chaiyakunapruk, Nilawan Upakdee, Peerapon Wong. (2011) Iron-Chelating Therapies in a Transfusion-Dependent Thalassaemia Population in Thailand. Clinical Drug Investigation 31:7, 493-505
CrossRef5
Jaroslav Cermak, Anna Jonasova, Jana Vondrakova, Lenka Walterova, Ivana Hochova, Magda Siskova, Radana Neuwirtova. (2011) Efficacy And Safety Of Administration Of Oral Iron Chelator Deferiprone In Patients With Early Myelodysplastic Syndrome. Hemoglobin 35:3, 217-227
CrossRef6
Hussain I. Saba, Arshia A. Dangol, Donald C. Doll. 2011. Supportive Care in Myelodysplastic Syndrome. , 172-190.
CrossRef7
Katherine H. Thompson. 2011. Medicinal Inorganic Chemistry: Sequestration or Removal in Metal Ion Overload Disorders. .
CrossRef8
Vasilios Berdoukas, Kallistheni Farmaki, John C Wood, Thomas Coates. (2011) Iron chelation in thalassemia: time to reconsider our comfort zones. Expert Review of Hematology 4:1, 17-26
CrossRef9
Adlette Inati, Evelyne Khoriaty, Khaled M. Musallam. (2011) Iron in sickle-cell disease: What have we learned over the years?. Pediatric Blood & Cancer 56:2, 182-190
CrossRef10
John B. Porter, Farrukh T. Shah. (2010) Iron Overload in Thalassemia and Related Conditions: Therapeutic Goals and Assessment of Response to Chelation Therapies. Hematology/Oncology Clinics of North America 24:6, 1109-1130
CrossRef11
Adlette Inati, Evelyne Khoriaty, Khaled M. Musallam, Ali T. Taher. (2010) Iron chelation therapy for patients with sickle cell disease and iron overload. American Journal of Hematology 85:10, 782-786
CrossRef12
Renzo Galanello, Annalisa Agus, Simona Campus, Fabrice Danjou, Patricia J. Giardina, Robert W. Grady. (2010) Combined iron chelation therapy. Annals of the New York Academy of Sciences 1202:1, 79-86
CrossRef13
2010. References. , 529-685.
CrossRef14
Janet L. Kwiatkowski. (2010) Oral Iron Chelators. Hematology/Oncology Clinics of North America 24:1, 229-248
CrossRef15
Inusha Panigrahi, Ram K. Marwaha, Rashmi R. Das, Amita Trehan, Deepak Bansal. (2010) Long-term response to deferiprone therapy in Asian Indians. Annals of Hematology 89:2, 135-140
CrossRef16
Vinod Pullarkat. (2010) Iron Overload in Patients Undergoing Hematopoietic Stem Cell Transplantation. Advances in Hematology 2010, 1-12
CrossRef17
Hussam Ghoti, Orly Goitein, Ariel Koren, Carina Levin, Tamar Kushnir, Eliezer Rachmilewitz, Eli Konen. (2010) No evidence for myocardial iron overload and free iron species in multitransfused patients with sickle/β0-thalassaemia. European Journal of Haematology 84:1, 59-63
CrossRef18
Sung Chul Won, Dong Kyun Han, Jong Jin Seo, Nak Gyun Chung, Sang Kyu Park, Kyung Bae Park, Hoon Kook, Chuhl Joo Lyu. (2010) Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients. The Korean Journal of Hematology 45:1, 58
CrossRef19
L. A. Verduzco, D. G. Nathan. (2009) Sickle cell disease and stroke. Blood 114:25, 5117-5125
CrossRef20
Ali Taher, Chaim Hershko, Maria Domenica Cappellini. (2009) Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. British Journal of Haematology 147:5, 634-640
CrossRef21
Aurelio Maggio, Angela Vitrano, Marcello Capra, Liana Cuccia, Francesco Gagliardotto, Aldo Filosa, Maria Antonietta Romeo, Carmelo Magnano, Vincenzo Caruso, Crocetta Argento, Calogera Gerardi, Saveria Campisi, Pietro Violi, Roberto Malizia, Paolo Cianciulli, Michele Rizzo, Domenico Giuseppe D’Ascola, Alessandra Quota, Luciano Prossomariti, Carmelo Fidone, Paolo Rigano, Alessia Pepe, Gennaro D’Amico, Alberto Morabito, Christian Gluud. (2009) Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. British Journal of Haematology 145:2, 245-254
CrossRef22
Yutaka Kohgo, Katsuya Ikuta, Takaaki Ohtake, Yoshihiro Torimoto, Junji Kato. (2008) Body iron metabolism and pathophysiology of iron overload. International Journal of Hematology 88:1, 7-15
CrossRef23
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns. (2008) High Prevalence of Iron Overload in Adult Allogeneic Hematopoietic Cell Transplant Survivors. Biology of Blood and Marrow Transplantation 14:7, 790-794
CrossRef24
Himanshu Goel, K. M. Girisha, Shubha R. Phadke. (2008) Long-term efficacy of oral deferiprone in management of iron overload in beta thalassemia major. Hematology 13:2, 77-82
CrossRef25
Janet L. Kwiatkowski. (2008) Oral Iron Chelators. Pediatric Clinics of North America 55:2, 461-482
CrossRef26
Sameer Mahesh, Yelena Ginzburg, Amit Verma. (2008) Iron overload in myelodysplastic syndromes. Leukemia & Lymphoma 49:3, 427-438
CrossRef27
Thomas E. Delea, John Edelsberg, Oleg Sofrygin, Simu K. Thomas, Jean-Francois Baladi, Pradyumna D. Phatak, Thomas D. Coates. (2007) Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 47:10, 1919-1929
CrossRef28
David Roberts, Susan Brunskill, Carolyn Doree, Senani Williams, Jo Howard, Chris Hyde, David Roberts. 2007. Oral deferiprone for iron chelation in people with thalassaemia. .
CrossRef29
Lawrence Tim Goodnough. (2007) Erythropoietin and iron-restricted erythropoiesis. Experimental Hematology 35:4, 167-172
CrossRef30
Ali Taher, David Nathan, John Porter. (2007) Evaluation of Iron Levels to Avoid the Clinical Sequelae of Iron Overload. Seminars in Hematology 44, S2-S6
CrossRef31
James C Barton. (2007) Optimal Management Strategies for Chronic Iron Overload. Drugs 67:5, 685-700
CrossRef32
Lawrence Tim Goodnough. (2006) The Relevance of Iron in Erythropoietin-Stimulated Erythropoiesis. Seminars in Hematology 43, S3-S8
CrossRef33
2006. Deferiprone. , 1054-1058.
CrossRef34
Katherine H. Thompson, Cheri A. Barta, Chris Orvig. (2006) Metal complexes of maltol and close analogues in medicinal inorganic chemistry. Chemical Society Reviews 35:6, 545
CrossRef35
ROLAND FISCHER, ANTONIO PIGA, PAUL HARMATZ, PETER NIELSEN. (2005) Monitoring Long-Term Efficacy of Iron Chelation Treatment with Biomagnetic Liver Susceptometry. Annals of the New York Academy of Sciences 1054:1, 350-357
CrossRef36
David Roberts, David Rees, Jo Howard, Chris Hyde, Susan Brunskill, David Roberts. 2005. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. .
CrossRef37
Massimo Franchini. (2005) Recent acquisitions in the management of iron overload. Annals of Hematology 84:10, 640-645
CrossRef38
A. Piga, S. Roggero, F. Marletto, L. Sacchetti, F. Longo. (2005) Combined use of oral chelators and desferrioxamine in thalassemia. Hematology 10:4, 89-91
CrossRef39
Chiang W. Siah, Debbie Trinder, John K. Olynyk. (2005) Iron overload. Clinica Chimica Acta 358:1-2, 24-36
CrossRef40
Ersi Voskaridou, Maroussa Douskou, Evangelos Terpos, Alexandra Stamoulakatou, John Meletis, Akis Ourailidis, Ioannis Papassotiriou, Dimitris Loukopoulos. (2005) Deferiprone as an oral iron chelator in sickle cell disease. Annals of Hematology 84:7, 434-440
CrossRef41
J.B. Porter. (2005) Monitoring and treatment of iron overload: State of the art and new approaches. Seminars in Hematology 42:2, S14-S18
CrossRef42
Janet L. Kwiatkowski, Alan R. Cohen. (2004) Iron chelation therapy in sickle-cell disease and other transfusion-dependent anemias. Hematology/Oncology Clinics of North America 18:6, 1355-1377
CrossRef43
Ersi Voskaridou, Maroussa Douskou, Evangelos Terpos, Ioannis Papassotiriou, Alexandra Stamoulakatou, Akis Ourailidis, Aphroditi Loutradi, Dimitris Loukopoulos. (2004) Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease. British Journal of Haematology 126:5, 736-742
CrossRef44
G.C.F. Chan, D.M.W. Ng, D.Y.T. Fong, S.Y. Ha, Y.L. Lau. (2004) Comparison of subcutaneous infusion needles for transfusion-dependent thalassemia patients by the intrapersonal cross-over assessment model. American Journal of Hematology 76:4, 398-404
CrossRef45
D Roberts, D Rees, J Howard, S Williams, C Hyde, S Brunskill, David Roberts. 2004. Oral deferiprone for iron chelation in people with thalassaemia. .
CrossRef46
Emanuela DʼAngelo, Nadia Mirra, Alice Rocca, Vittorio Carnelli. (2004) Combined Therapy With Desferrioxamine and Deferiprone: A New Protocol for Iron Chelation in Thalassemia. Journal of Pediatric Hematology/Oncology 26:7, 451-453
CrossRef47
Karen F Murray, Dickson Lam, Kris V Kowdley. (2003) Current and future therapy in haemochromatosis and Wilson’s disease. Expert Opinion on Pharmacotherapy 4:12, 2239-2251
CrossRef48
D Roberts, D Rees, J Howard, C Hyde, S Stanworth, S Brunskill. 2003. Desferrioxamine mesylate for managing transfusional iron overload in people with thalassaemia. .
CrossRef49
Adriana Ceci, Mariagrazia Felisi, Vincenzo De Sanctis, Domenico De Mattia. (2003) Pharmacotherapy of iron overload in thalassaemic patients. Expert Opinion on Pharmacotherapy 4:10, 1763-1774
CrossRef50
Timothy B. Chaston, Des R. Richardson. (2003) Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity. American Journal of Hematology 73:3, 200-210
CrossRef51
Roland Fischer, Filomena Longo, Peter Nielsen, Rainer Engelhardt, Robert C. Hider, Antonio Piga. (2003) Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. British Journal of Haematology 121:6, 938-948
CrossRef52
Ching-Tien Peng, Kuan-Chih Chow, Jeon-Hor Chen, Yi-Ping Chiang, Tze-Yi Lin, Chang-Hai Tsai. (2003) Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in Taiwan. European Journal of Haematology 70:6, 392-397
CrossRef53
Eric Nisbet-Brown, Nancy F Olivieri, Patricia J Giardina, Robert W Grady, Ellis J Neufeld, Romain Séchaud, Axel J Krebs-Brown, Judith R Anderson, Daniele Alberti, Kurt C Sizer, David G Nathan. (2003) Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. The Lancet 361:9369, 1597-1602
CrossRef54
Nancy F. Olivieri. (2003) Patients’ health or company profits? The commercialisation of academic research. Science and Engineering Ethics 9:1, 29-41
CrossRef55
Nathan, David G., , Weatherall, David J., . (2002) Academic Freedom in Clinical Research. New England Journal of Medicine 347:17, 1368-1371
Full Text56
Des R Richardson. (2002) Deferiprone: greater efficacy at depleting myocardial than hepatic iron?. The Lancet 360:9332, 501-502
CrossRef57
Lisa J Anderson, Beatrix Wonke, Emma Prescott, Sally Holden, J Malcolm Walker, Dudley J Pennell. (2002) Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. The Lancet 360:9332, 516-520
CrossRef58
Adriana Ceci, Paola Baiardi, Mariagrazia Felisi, Maria Domenica Cappellini, Vittorio Carnelli, Vincenzo De Sanctis, Renzo Galanello, Aurelio Maggio, Giuseppe Masera, Antonio Piga, Francesco Schettini, Ippazio Stefano, Fernando Tricta. (2002) The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. British Journal of Haematology 118:1, 330-336
CrossRef59
Aurelio Maggio, Gennaro D'Amico, Alberto Morabito, Marcello Capra, Calogero Ciaccio, Paolo Cianciulli, Felicia Di Gregorio, Giovanni Garozzo, Roberto Malizia, Carmelo Magnano, Antonino Mangiagli, Giovanni Quarta, Michele Rizzo, Domenico Giuseppe D'Ascola, Aroldo Rizzo, Massimo Midiri. (2002) Deferiprone versus Deferoxamine in Patients with Thalassemia Major: A Randomized Clinical Trial. Blood Cells, Molecules, and Diseases 28:2, 196-208
CrossRef60
Xi Huang, Jisen Dai, Jeanine Fournier, Aktar M. Ali, Qi Zhang, Krystyna Frenkel. (2002) Ferrous ion autoxidation and its chelation in iron-loaded human liver HepG2 cells. Free Radical Biology and Medicine 32:1, 84-92
CrossRef61
Antonios Kattamis, Argyris Dinopoulos, Vassilios Ladis, Helen Berdousi, Christos Kattamis. (2001) Variations of ferritin levels over a period of 15 years as a compliance chelation index in thalassemic patients. American Journal of Hematology 68:4, 221-224
CrossRef62
John B. Porter. (2001) Practical management of iron overload. British Journal of Haematology 115:2, 239-252
CrossRef63
Patricia J Giardina, Robert W Grady. (2001) Chelation therapy in β-thalassemia: An optimistic update. Seminars in Hematology 38:4, 360-366
CrossRef64
Ami J. Claxton, Joyce Cramer, Courtney Pierce. (2001) A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics 23:8, 1296-1310
CrossRef65
Kofi A Anie, Pia Massaglia, Kofi A Anie. 2001. Psychological therapies for thalassaemia. .
CrossRef66
Ali Taher, Marwan Sheikh-Taha, Suzanne Koussa, Adlette Inati, Roger Neeman, Fadi Mourad. (2001) Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. European Journal of Haematology 67:1, 30-34
CrossRef67
Marco Borsari, Cristina Gabbi, Franco Ghelfi, Romano Grandi, Monica Saladini, Stefano Severi, Fabio Borella. (2001) Silybin, a new iron-chelating agent. Journal of Inorganic Biochemistry 85:2-3, 123-129
CrossRef68
Dibyendu Chakraborty, Maitree Bhattacharyya. (2001) Antioxidant defense status of red blood cells of patients with β-thalassemia and Eβ-thalassemia. Clinica Chimica Acta 305:1-2, 123-129
CrossRef69
Gary M Brittenham, Sujit Sheth, Christopher J Allen, David E Farrell. (2001) Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. Seminars in Hematology 38, 37-56
CrossRef70
Chaim Hershko, A. Victor Hoffbrand. (2000) Iron chelation therapy. Reviews in Clinical and Experimental Hematology 4:4, 337-361
CrossRef71
Peter M. Ihnat, Jonathan L. Vennerstrom, Dennis H. Robinson. (2000) Synthesis and solution properties of deferoxamine amides. Journal of Pharmaceutical Sciences 89:12, 1525-1536
CrossRef72
M. J. Pippard, D. J. Weatherall. (2000) Oral iron chelation therapy for thalassaemia: an uncertain scene. Annotation. British Journal of Haematology 111:1, 2-5
CrossRef73
M. J. Pippard, D. J. Weatherall. (2000) Oral iron chelation therapy for thalassaemia: an uncertain scene. British Journal of Haematology 111:1, 2-5
CrossRef74
Abraham Kohan, Ricardo Niborski, Jorge Daruich, Jorge Rey, Fabiana Bastos, Graciela Amerise, Roberto Herrera, Marcelo Garcia, Walter Olivera, Maria Teresa Santarelli, Julio Sanchez Avalos, Jorge Findor. (2000) Erythrocytapheresis with Recombinant Human Erythropoietin in Hereditary Hemochromatosis Therapy: A New Alternative. Vox Sanguinis 79:1, 40-45
CrossRef75
Robert A. Yokel, Andrea M. Fredenburg, Patricia W. Durbin, Jide Xu, Mary Kay Rayens, Kenneth N. Raymond. (2000) The hexadentate hydroxypyridinonate TREN-(Me-3,2-HOPO) is a more orally active iron chelator than its bidentate analogue. Journal of Pharmaceutical Sciences 89:4, 545-555
CrossRef76
Deborah Rund, Eliezer Rachmilewitz. (2000) New trends in the treatment of β-thalassemia. Critical Reviews in Oncology/Hematology 33:2, 105-118
CrossRef77
Cohen, Galanello, Piga, DiPalma, Vullo, Tricta. (2000) Safety profile of the oral iron chelator deferiprone: a multicentre study. British Journal of Haematology 108:2, 305-312
CrossRef78
N Rakba, M.K Nguyen-Van-Duong, L Nicolas, V Guillot, I Morel, N Pasdeloup, P Brissot, G Lescoat. (1999) Cytoprotection and iron mobilization in rat hepatocyte cultures by a new synthetic dihydroxamate chelator. Toxicology Letters 110:1-2, 19-27
CrossRef79
I. Pashalidis, G. J. Kontoghiorghes. (1999) Effective complex formation in the interaction of 1,2-dimethyl-3-hydroxypyrid-4-one (Deferiprone or L1) with uranium(VI). Journal of Radioanalytical and Nuclear Chemistry 242:1, 181-184
CrossRef80
Olivieri, Nancy F., . (1999) The β-Thalassemias. New England Journal of Medicine 341:2, 99-109
Full Text81
John W. Adamson, Ivor Cavill, Steven Fishbane, Jeffrey Petersen, Jay B. Wish. (1999) A Consensus on Current Issues and Controversies in Iron Management of Patients with Chronic Renal Failure. Seminars in Dialysis 12:3, 182-194
CrossRef82
Gavino Faa, Guido Crisponi. (1999) Iron chelating agents in clinical practice. Coordination Chemistry Reviews 184:1, 291-310
CrossRef83
DG Nathan, DJ Weatherall. (1999) Academia and industry: lessons from the unfortunate events in Toronto. The Lancet 353:9155, 771-772
CrossRef84
Orna Diav-Citrin, Gordana Atanackovic, Gideon Koren. (1999) An Investigation Into Variability in the Therapeutic Response to Deferiprone in Patients With Thalassemia Major. Therapeutic Drug Monitoring 21:1, 74-81
CrossRef85
(1998) Iron Chelation with Oral Deferiprone in Patients with Thalassemia. New England Journal of Medicine 339:23, 1710-1714
Full Text86
Jean-Baptiste Galey, Odile Destrée, Jacqueline Dumats, Patrick Pichaud, Johann Marché, Sylvie Génard, Giovanni Bracciolli, Laurence Le Capitaine, Hervé Plessix, Liliana Brambilla. (1998) Protection of U937 cells against oxidative injury by a novel series of iron chelators. Free Radical Biology and Medicine 25:8, 881-890
CrossRef87
V. P. Choudhry. (1998) Annotation: Oral deferiprone — controversies on its efficacy and safety. The Indian Journal of Pediatrics 65:6, 825-828
CrossRef88
Wonke, Wright, Hoffbrand. (1998) Combined therapy with deferiprone and desferrioxamine. British Journal of Haematology 103:2, 361-364
CrossRef89
Olivieri, Nancy F., Brittenham, Gary M., McLaren, Christine E., Templeton, Douglas M., Cameron, Ross G., McClelland, Robert A., Burt, Alastair D., Fleming, Kenneth A., . (1998) Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia Major. New England Journal of Medicine 339:7, 417-423
Full Text90
Kowdley, Kris V., , Kaplan, Marshall M., . (1998) Iron-Chelation Therapy with Oral Deferiprone — Toxicity or Lack of Efficacy?. New England Journal of Medicine 339:7, 468-469
Full Text91
D.R. Richardson, P. Ponka. (1998) Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. American Journal of Hematology 58:4, 299-305
CrossRef92
ALAN COHEN, RENZO GALANELLO, ANTONIO PIGA, CALOGERO VULLO, FERNANDO TRICTA. (1998) A Multi-Center Safety Trial of the Oral Iron Chelator Deferiprone. Annals of the New York Academy of Sciences 850:1 COOLEY'S ANEM, 223-226
CrossRef93
Chaim Hershko, Abraham M. Konijn, Gabriela Link. (1998) Iron Chelators for Thalassaemia. British Journal of Haematology 101:3, 399-406
CrossRef94
NANCY F. OLIVIERI, GARY M. BRITTENHAM. (1998) Long-Term Trials of Deferiprone in Cooley's Anemiaa. Annals of the New York Academy of Sciences 850:1 COOLEY'S ANEM, 217-222
CrossRef95
Nancy Olivieri. (1998) 5 Thalassaemia: clinical management. Baillière's Clinical Haematology 11:1, 147-162
CrossRef96
Patrick Jégo, Norchen Chenoufl, Olivier Loréal, Isabelle Morel, Nicole Pasdeloup, Mohamed A. Abdallah, Pierre Brissot, Gérard Lescoat. (1997) Inhibition of iron toxicity in human hepatocyte cultures by pyoverdins Pa A and Pf, the peptidic siderophores of Pseudomonas aeruginosa and fluorescens. Liver 17:2, 70-75
CrossRef97
D.J. Weatherall, J.B. Clegg. (1996) Thalassemia — a global public health problem. Nature Medicine 2:8, 847-849
CrossRef98
Maria Grazia Marciani, Cesare Iani, Maria Teresa Desiato, Francesca Spanedda, Maria Antonietta Bassetti, Paolo Cianciulli. (1996) Subclinical auditory and visual involvement during oral deferiprone therapy. American Journal of Hematology 51:2, 179-180
CrossRef99
Lori A. Styles, Elliott P. Vichinsky. (1996) Ototoxicity in Hemoglobinopathy Patients Chelated with Desferrioxamine. Journal of Pediatric Hematology/Oncology 18:1, 42-45
CrossRef100
Norishi Ueda, Radhakrishna Baliga, Sudhir V Shah. (1996) Role of ‘catalytic’ iron in an animal model of minimal change nephrotic syndrome. Kidney International 49:2, 370-373
CrossRef101
R. Lange, W. Lameijer, C. Slijkhuis, D. Kaste. (1996) Pharmaceutical analysis of the oral iron chelator deferiprone (DMHP, L1). Pharmacy World and Science 18:4, 142-147
CrossRef102
Alvin Zipursky. (1996) Hematology and Oncology at the Hospital for Sick Children. Pediatric Hematology-Oncology 13:5, 391-395
CrossRef103
P. Nielsen, R. Fischer, R. Engelhardt, P. Tondüry, E. E. Gabbe, G. E. Janka. (1995) Liver iron stores in patients with secondary haemosiderosis under iron chelation therapy with deferoxamine or deferiprone. British Journal of Haematology 91:4, 827-833
CrossRef104
P. Rebulla. (1995) Blood transfusion in beta thalassaemia major. Transfusion Medicine 5:4, 247-258
CrossRef105
(1995) Deferiprone in Iron Overload. New England Journal of Medicine 333:9, 597-599
Full Text106
Nathan, David G., . (1995) An Orally Active Iron Chelator. New England Journal of Medicine 332:14, 953-954
Full Text
- Letters
